New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program

28 February, 2017

microRNA-520f reverses epithelial-to-mesenchymal transition by targeting ADAM9 and TGFBR2 Cancer Research 2017